Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Radiation Oncology Physician in Fort Wayne, IN
NPI: 1245364926Primary Practice Location
PARKVIEW REGIONAL MEDICAL CENTER
2200 Randallia Dr, Fort Wayne, IN
Primary Employer
Radiation Oncology Associates P C
roafw.com
HQ Phone
Get M.D. Brian's Phone Numberphone_androidMobile
Get M.D. Brian's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License
OH State Medical License
2020 - 2026
IN State Medical License
2007 - 2025
IA State Medical License
2003 - 2007
PA State Medical License
2002 - 2003
American Board of Radiology
Radiation Oncology
Tufts University School Of Medicine
medicine.tufts.edu
Medical School
Until 2002
University of Texas Southwestern Medical Center
Residency • Radiation Oncology
2005 - 2007
University of Iowa Hospitals and Clinics
Residency • Radiation Oncology
2003 - 2005
UPMC Medical Education (Mercy)
Internship • Transitional Year
2002 - 2003
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 77014Ct scan guidance for insertion of radiation therapy fields | 111 | 895 |
| 2 | 77427Radiation treatment management, 5 treatment sessions | 94 | 294 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 91 | 91 |
| 4 | 77334Design and construction of complex radiation treatment device | 77 | 242 |
| 5 | 77263Complex radiation therapy planning | 77 | 80 |
Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
Authors: Christopher Sande
Publication Date: 2017-11-16
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Authors: Howard Sandler, Douglas Dahl, William Shipley, Gregory Swanson, John Ellerton, Anthony Zietman, Jason Efstathiou, Marc Michaelson, Richard Deming, Jacqueline Vuky, Huong Pham
Publication Date: 2024-02
Authors: Howard Sandler, Douglas Dahl, Gregory Swanson, Marc Michaelson, Asha George, Jacqueline Vuky, Huong Pham
Publication Date: 2016-12-19
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab, DRUG: Gemcitabine, DRUG: Pemetrexed Disodium, DRUG: Erlotinib Hydrochloride, RADIATION: Stereotactic Body Radiation Therapy (SBRT), RADIATION: Intensity-Modulated Radiation Therapy (IMRT), RADIATION: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Lead Sponsor: NovoCure Ltd.
Intervention / Treatment: DEVICE: Optune®
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: RADIATION: External Beam Radiation Therapy, OTHER: Placebo Administration, DRUG: Apalutamide
